Patients With Relapsed Refractory Mantle Cell Lymphoma clinical trials

Explore recruiting patients with relapsed refractory mantle cell lymphoma clinical trials.

Recruiting patients with relapsed refractory mantle cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Patients With Relapsed Refractory Mantle Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy of Polatuzumab, Bendamustine and Rituximab in patients with relapsed/refractory mantle cell lymphoma- A single center phase II trial

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients (OAsIs)

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A PHASE III, OPEN-LABEL, MULTICENTER RANDOMIZED STUDY EVALUATING GLOFITAMAB AS A SINGLE AGENT VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Italy, France, Sweden, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Germany, France, Italy, Poland, Spain, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Patients With Relapsed Refractory Mantle Cell Lymphoma trials by city

Patients With Relapsed Refractory Mantle Cell Lymphoma in Toronto Patients With Relapsed Refractory Mantle Cell Lymphoma in Vancouver Patients With Relapsed Refractory Mantle Cell Lymphoma in Montreal Patients With Relapsed Refractory Mantle Cell Lymphoma in Calgary Patients With Relapsed Refractory Mantle Cell Lymphoma in Edmonton Patients With Relapsed Refractory Mantle Cell Lymphoma in Ottawa Patients With Relapsed Refractory Mantle Cell Lymphoma in Winnipeg Patients With Relapsed Refractory Mantle Cell Lymphoma in Quebec City Patients With Relapsed Refractory Mantle Cell Lymphoma in Hamilton Patients With Relapsed Refractory Mantle Cell Lymphoma in Kitchener Patients With Relapsed Refractory Mantle Cell Lymphoma in London Patients With Relapsed Refractory Mantle Cell Lymphoma in Halifax Patients With Relapsed Refractory Mantle Cell Lymphoma in New York Patients With Relapsed Refractory Mantle Cell Lymphoma in Los Angeles Patients With Relapsed Refractory Mantle Cell Lymphoma in Chicago Patients With Relapsed Refractory Mantle Cell Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease